Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Recent patents report new possible treatment options anxiety, depression, psychosis, etc.

May 6, 2005

Requip approved for moderate to severe primary restless legs syndrome

May 6, 2005

Positive effects of CX-717 in human sleep deprivation study

May 6, 2005

Botulinum toxin type A demonstrates potential in chronic daily headache

May 5, 2005

New follow-on phase II study of M-40403 and morphine in postsurgical pain

May 5, 2005

Preliminary data on the efficacy of Flurizan in Alzheimer's disease

May 5, 2005

New therapies for neurological disorders claimed in recent patent literature

May 5, 2005

Roche makes milestone payment to retain option to MEM-3454

May 5, 2005

NGF gene therapy shows promise in the treatment of Alzheimer's disease

May 5, 2005

Pharmacokinetics and pharmacodynamics of CHF-3381 studied in healthy volunteers

May 4, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...